NASDAQ:IRMD Iradimed (IRMD) Stock Price, News & Analysis $53.70 +0.68 (+1.28%) Closing price 04/29/2025 04:00 PM EasternExtended Trading$53.54 -0.16 (-0.29%) As of 04/29/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Iradimed Stock (NASDAQ:IRMD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Iradimed alerts:Sign Up Key Stats Today's Range$53.00▼$54.1450-Day Range$48.67▼$56.2452-Week Range$40.55▼$63.29Volume20,064 shsAverage Volume44,310 shsMarket Capitalization$682.80 millionP/E Ratio35.80Dividend Yield1.27%Price Target$72.00Consensus RatingBuy Company OverviewIRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.Read More… Iradimed Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks97th Percentile Overall ScoreIRMD MarketRank™: Iradimed scored higher than 97% of companies evaluated by MarketBeat, and ranked 33rd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingIradimed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageIradimed has only been the subject of 1 research reports in the past 90 days.Read more about Iradimed's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth20.48% Earnings GrowthEarnings for Iradimed are expected to grow by 20.48% in the coming year, from $1.66 to $2.00 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Iradimed is 35.80, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 21.90.Price to Earnings Ratio vs. SectorThe P/E ratio of Iradimed is 35.80, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 22.40.Price to Book Value per Share RatioIradimed has a P/B Ratio of 9.49. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Iradimed's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted2.58% of the float of Iradimed has been sold short.Short Interest Ratio / Days to CoverIradimed has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in Iradimed has recently increased by 9.94%, indicating that investor sentiment is decreasing significantly. Dividend2.5 / 5Dividend StrengthModerate Dividend YieldIradimed pays a meaningful dividend of 1.28%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthIradimed does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Iradimed is 45.33%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Iradimed will have a dividend payout ratio of 34.00% next year. This indicates that Iradimed will be able to sustain or increase its dividend.Read more about Iradimed's dividend. Sustainability and ESG4.4 / 5Environmental Score-0.85 Percentage of Shares Shorted2.58% of the float of Iradimed has been sold short.Short Interest Ratio / Days to CoverIradimed has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in Iradimed has recently increased by 9.94%, indicating that investor sentiment is decreasing significantly. News and Social Media3.3 / 5News Sentiment1.00 News SentimentIradimed has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.85 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Iradimed this week, compared to 2 articles on an average week.Search Interest1 people have searched for IRMD on MarketBeat in the last 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Iradimed insiders have not sold or bought any company stock.Percentage Held by Insiders37.10% of the stock of Iradimed is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions92.34% of the stock of Iradimed is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Iradimed's insider trading history. Receive IRMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Iradimed and its competitors with MarketBeat's FREE daily newsletter. Email Address IRMD Stock News HeadlinesCORRECTION -- IRADIMED CORPORATION to Hold First Quarter of 2025 Financial Results Conference Call on May 5, 2025April 28 at 9:53 AM | globenewswire.comIRADIMED CORPORATION to Hold First Quarter of 2025 Financial Results Conference Call on May 5, 2025April 28 at 8:30 AM | globenewswire.comTop performing AI play of the decade…? (The answer will shock you)You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is about to announce could change the AI market once again. Experts already predict the total addressable market could climb past $20 trillion. But Sykes believes most investors have missed what’s coming next. He’s tracking a new shift — and says the biggest gains are still ahead.April 30, 2025 | Timothy Sykes (Ad)StockNews.com Upgrades Iradimed (NASDAQ:IRMD) to Strong-BuyApril 27 at 1:53 AM | americanbankingnews.comiRadimed Corporation Common Stock (IRMD)April 24, 2025 | nasdaq.comUndiscovered Gems in the US Market for April 2025April 11, 2025 | finance.yahoo.comIRadimed Corporation: Steady, Low-Risk Grower In The Devices SpaceApril 8, 2025 | seekingalpha.comIRADIMED CORPORATION To Participate at the 37th Annual Roth ConferenceMarch 10, 2025 | globenewswire.comSee More Headlines IRMD Stock Analysis - Frequently Asked Questions How have IRMD shares performed this year? Iradimed's stock was trading at $55.00 at the beginning of 2025. Since then, IRMD shares have decreased by 2.4% and is now trading at $53.70. View the best growth stocks for 2025 here. How were Iradimed's earnings last quarter? Iradimed Corporation (NASDAQ:IRMD) announced its earnings results on Thursday, February, 13th. The medical equipment provider reported $0.40 earnings per share for the quarter, missing analysts' consensus estimates of $0.45 by $0.05. The medical equipment provider earned $19.39 million during the quarter, compared to analyst estimates of $19.09 million. Iradimed had a net margin of 26.26% and a trailing twelve-month return on equity of 24.12%. Read the conference call transcript. Who are Iradimed's major shareholders? Top institutional shareholders of Iradimed include Copeland Capital Management LLC (3.86%), Bank of New York Mellon Corp (0.80%), Envestnet Asset Management Inc. (0.55%) and Bridge City Capital LLC (0.48%). Insiders that own company stock include Roger E Susi, James B Hawkins, Monty K Allen, Anthony Vuoto and John Glenn. View institutional ownership trends. How do I buy shares of Iradimed? Shares of IRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Iradimed own? Based on aggregate information from My MarketBeat watchlists, some other companies that Iradimed investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Broadcom (AVGO) and Alphabet (GOOG). Company Calendar Last Earnings2/13/2025Record date for 3/5 Dividend2/24/2025Ex-Dividend for 3/5 Dividend2/24/2025Dividend Payable3/05/2025Today4/29/2025Next Earnings (Estimated)5/01/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:IRMD CIK1325618 Webwww.iradimed.com Phone(407) 677-8022Fax407-677-5037Employees110Year FoundedN/APrice Target and Rating Average Stock Price Target$72.00 High Stock Price Target$72.00 Low Stock Price Target$72.00 Potential Upside/Downside+34.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)$1.50 Trailing P/E Ratio35.80 Forward P/E Ratio32.35 P/E GrowthN/ANet Income$19.23 million Net Margins26.26% Pretax Margin33.11% Return on Equity24.12% Return on Assets21.20% Debt Debt-to-Equity RatioN/A Current Ratio9.21 Quick Ratio7.82 Sales & Book Value Annual Sales$73.24 million Price / Sales9.32 Cash Flow$1.34 per share Price / Cash Flow40.12 Book Value$5.66 per share Price / Book9.49Miscellaneous Outstanding Shares12,715,000Free Float7,971,000Market Cap$682.80 million OptionableOptionable Beta0.82 Social Links The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:IRMD) was last updated on 4/30/2025 by MarketBeat.com Staff From Our PartnersTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | Sponsored#1 AI play of the decade…? (The answer will shock you)Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iradimed Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Iradimed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.